Catherine Eckford

3 weeks ago | europeanpharmaceuticalreview.com | Catherine Eckford

Posted: 6 June 2025 | Catherine Eckford (European Pharmaceutical Review) | The gene therapy demonstrated consistent evidence of positively changing disease trajectory in Duchenne muscular dystrophy, new interim data shows. New positive interim trial data has demonstrated that a potential best-in-class gene therapy can provide meaningful functional improvements in Duchenne muscular dystrophy. These new findings are from the Phase I/II AFFINITY DUCHENNE clinical trial for RGX-202.

3 weeks ago | europeanpharmaceuticalreview.com | Catherine Eckford

Posted: 5 June 2025 | Catherine Eckford (European Pharmaceutical Review) | MHRA’s publication is intended to support European developers of phage-based medicinal products to effectively navigate related regulations. The Medicines and Healthcare products Regulatory Agency (MHRA) has published the UK’s first official guidance on safe development and use of phage therapies. The publication collates UK and international regulatory standards on phage therapies into one place.

3 weeks ago | europeanpharmaceuticalreview.com | Catherine Eckford

Posted: 4 June 2025 | Catherine Eckford (European Pharmaceutical Review) | The new EU rules for medicines aims to strengthen EU pharmaceutical competitiveness and reduce the regulatory burden. The European Council is set to begin negotiations with the European Parliament about the pharma package, having agreed its position on the new rules. The proposals comprise of a regulation and directive. Once in place, the package will represent the biggest pharmaceutical reform in over twenty years.

3 weeks ago | europeanpharmaceuticalreview.com | Catherine Eckford

Posted: 3 June 2025 | Catherine Eckford (European Pharmaceutical Review) | The agreement involves an immunotherapy candidate with potential to innovate treatment of multiple tumour types, stated BMS. BioNTech SE and Bristol Myers Squibb (BMS) have agreed a collaboration to advance a bispecific antibody, setting the stage for a potential new standard of care in cancer. BMS will pay BioNTech $1.5 billion upfront and $2 billion total in non-contingent anniversary payments through 2028.

3 weeks ago | europeanpharmaceuticalreview.com | Catherine Eckford

Posted: 2 June 2025 | Catherine Eckford (European Pharmaceutical Review) | Advanced technology innovation is driving lower R&D costs and progress of targeted treatments such as cell and gene therapies, the research reports. According to research by Medi-Tech Insights, the global biopharmaceutical market is expected to grow at a rate of 12 percent over the next five years. The authors explained that the market has an “optimistic view” about the remainder of 2025.